Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ANO1 | Q5XXA6 | 7/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | CTSA | P10619 | 2/20 | 0.46 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.43 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | APEX1 | P27695 | 1/20 | 0.41 |
| ▸ | KIT | P10721 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6415759 | 0.84 | CNR2 (0.47) | CTSA | |
| SCHEMBL4605525 | 0.81 | SMN1; SMN2 (0.48) | ANO1SMN1; SMN2RIPK1TRPV1KIT | |
| SCHEMBL30853475 | 0.81 | SMN1; SMN2 (0.48) | ANO1SMN1; SMN2RIPK1TRPV1KIT | |
| SCHEMBL14903854 | 0.81 | GAA (0.52) | CTSAKITTSHRGAA | |
| SCHEMBL6415070 | 0.80 | SMN1; SMN2 (0.47) | ANO1SMN1; SMN2RIPK1TRPV1POLB | |
| SCHEMBL22832228 | 0.80 | SMN1; SMN2 (0.47) | ANO1SMN1; SMN2RIPK1TSHRGAA | |
| SCHEMBL30139586 | 0.79 | CTSA (0.47) | CTSAKITTSHR | |
| SCHEMBL20913126 | 0.79 | CTSA (0.47) | CTSAKITTSHR | |
| SCHEMBL111380 | 0.77 | P2RX7 (0.52) | CTSAKITGAA | |
| SCHEMBL108122 | 0.77 | L3MBTL1 (0.60) | CTSATSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10022354-B2 | Pyrrolidine amide compounds as histone demethylase inhibitors | GENENTECH, INC. (US) | 2018-07-17 | — | — | US | disclosed |
| US-10022354-B2 | Pyrrolidine amide compounds as histone demethylase inhibitors | GENENTECH, INC. (US) | 2018-07-17 | — | — | US | disclosed |
| US-20170312252-A1 | PYRROLIDINE AMIDE COMPOUNDS AS HISTONE DEMETHYLASE INHIBITORS | WUXI APPTEC (SHANGHAI) CO. LTD (CN) | 2017-11-02 | — | — | US | disclosed |
| US-20170312252-A1 | PYRROLIDINE AMIDE COMPOUNDS AS HISTONE DEMETHYLASE INHIBITORS | WUXI APPTEC (SHANGHAI) CO. LTD (CN) | 2017-11-02 | — | — | US | disclosed |
| US-6936736-B2 | Amide derivative | SUMITOMO MANUFACTURING COMPANY LIMITED (JP) | 2005-08-30 | — | — | US | disclosed |
| EP-1034783-B1 | AMIDE DERIVATIVES FOR THE TREATMENT OF RETINAL NEURODEGENERATIVE DISORDERS | SUMITOMO PHARMA (JP) | 2004-12-15 | — | — | EP | disclosed |
| US-20020147204-A1 | Amide derivative | SUMITOMO PHARMACEUTICALS COMPANY, LIMITED | 2002-10-10 | — | — | US | disclosed |
| US-6384033-B1 | DRUGS FOR VISION DEFECTS | SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) | 2002-05-07 | — | — | US | disclosed |
| EP-1034783-A1 | AMIDE DERIVATIVES | SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) | 2000-09-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170312252-A1 | PYRROLIDINE AMIDE COMPOUNDS AS HISTONE DEMETHYLASE INHIBITORS | KDM5A, KDM5C, KDM5B | ANO1 4741/4885SMN1; SMN2 2278/4885CTSA 3334/4885 |
| US-10022354-B2 | Pyrrolidine amide compounds as histone demethylase inhibitors | KDM5A, KDM5C, KDM1B | ANO1 4744/4885SMN1; SMN2 2301/4885CTSA 3160/4885 |
| US-20020147204-A1 | Amide derivative | ALDH1A2, NR1H2, HDAC3 | ANO1 3084/4885SMN1; SMN2 2026/4885CTSA 1843/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.